Cargando…

Real-World Clinical Outcomes after Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer

Comprehensive genomic profiling for advanced non-small cell lung cancer (NSCLC) can identify patients for molecularly targeted therapies that improve clinical outcomes. We analyzed data from 3084 patients (median age 65 years, 72.9% with adenocarcinoma) with advanced NSCLC registered in a real-world...

Descripción completa

Detalles Bibliográficos
Autores principales:	Olsen, Steven, Liao, Jiemin, Hayashi, Hidetoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318660/ https://www.ncbi.nlm.nih.gov/pubmed/35877242 http://dx.doi.org/10.3390/curroncol29070382

Ejemplares similares

Comprehensive Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of a Real-World Healthcare Claims Database
por: Nakamura, Yoshiaki, et al.
Publicado: (2022)

Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
por: Alonso-García, Miriam, et al.
Publicado: (2022)

The real-world experience with nivolumab in previously treated patients with advanced non-small cell lung cancer from a cancer center in India
por: Abbas, Waseem, et al.
Publicado: (2020)

Clinical outcomes of Atezolizumab Therapy for Previously-Treated Advanced-Stage Non-Small Cell Lung Cancer: A Real-World Study in Taiwan
por: Wu, Shang-Gin, et al.
Publicado: (2022)

Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients
por: S. Ahmad, Saif, et al.
Publicado: (2015)

Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC
por: Ma, Xiya, et al.
Publicado: (2023)

Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study
por: Li, Li-Hua, et al.
Publicado: (2022)

Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study
por: Zhang, Song, et al.
Publicado: (2022)

Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis
por: Ljubicic, Lidija, et al.
Publicado: (2023)

Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients
por: Hua, G., et al.
Publicado: (2022)

Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort
por: Song, Yong, et al.
Publicado: (2020)

Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study
por: Gupta, Amol, et al.
Publicado: (2023)

Real‐world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice
por: Singal, Amit G., et al.
Publicado: (2022)

Mutation Profile Assessed by Next-Generation Sequencing (NGS) of Circulating Tumor DNA (ctDNA) in Chinese Lung Adenocarcinoma Patients: Analysis of Real-World Data
por: Zhao, Songchen, et al.
Publicado: (2021)

Personalized Treatment Selection and Disease Monitoring Using Circulating Tumor DNA Profiling in Real-World Cancer Patient Management
por: Wehrle, Julius, et al.
Publicado: (2020)

Association Between PDL1 Genetic Variation and Efficacy of Apatinib Monotherapy in Patients with Previously Treated Advanced NSCLC: A Real-World Retrospective Study
por: Hu, Wenxia, et al.
Publicado: (2021)

The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management
por: Fernandes, Maria Gabriela O., et al.
Publicado: (2021)

Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study
por: Gou, Miaomiao, et al.
Publicado: (2018)

The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
por: Wang, Fen, et al.
Publicado: (2021)

Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy
por: Bersanelli, Melissa, et al.
Publicado: (2014)

Cost-Effectiveness of Tislelizumab Versus Docetaxel for Previously Treated Advanced Non-Small-Cell Lung Cancer in China
por: Gong, Jinhong, et al.
Publicado: (2022)

Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study
por: Waddell, T., et al.
Publicado: (2022)

Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma
por: Wu, Qiuji, et al.
Publicado: (2022)

Role of Crizotinib in previously treated non-small-cell lung cancer
por: Gupta, Sunil Kumar
Publicado: (2014)

Real-world challenge for clinicians treating advanced gastroesophageal adenocarcinoma (Review)
por: Baxter, Mark A., et al.
Publicado: (2021)

Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors
por: Santoni, Matteo, et al.
Publicado: (2019)

Design of a Real-World Observational Study in Previously Untreated and Minimally Treated Hemophilia A Patients: Protect-NOW
por: Oldenburg, Johannes, et al.
Publicado: (2023)

Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer
por: Yao, Yu, et al.
Publicado: (2016)

Genomic profile of advanced breast cancer in circulating tumour DNA
por: Kingston, Belinda, et al.
Publicado: (2021)

A multicenter real-world study of tumor-derived DNA from pleural effusion supernatant in genomic profiling of advanced lung cancer
por: Jin, Shidai, et al.
Publicado: (2020)

Lorlatinib in previously treated anaplastic lymphoma kinase‐rearranged non–small cell lung cancer: Japanese subgroup analysis of a global study
por: Seto, Takashi, et al.
Publicado: (2020)

Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy
por: Coco, Simona, et al.
Publicado: (2017)

A Real-World Study in Advanced Non–Small Cell Lung Cancer with KRAS Mutations
por: Lei, Lei, et al.
Publicado: (2019)

Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer
por: Russo, Francesca, et al.
Publicado: (2008)

Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients
por: Zhang, Guan-Zhong, et al.
Publicado: (2010)

Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer
por: Lv, Weize, et al.
Publicado: (2022)

Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer
por: Hayashi, Hidetoshi, et al.
Publicado: (2011)

Monitoring Somatic Genetic Alterations in Circulating Cell-Free DNA/RNA of Patients with “Oncogene-Addicted” Advanced Lung Adenocarcinoma: A Real-World Clinical Study
por: Lupini, Laura, et al.
Publicado: (2022)

An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non–Small-Cell Lung Cancer
por: Stewart, Mark, et al.
Publicado: (2019)

Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan
por: Lin, Shu-Yung, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9vsimur06mbcqibac49jpll9lb